<b>Background/Objectives:</b> Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide well-established cardiovascular and renal benefits in heart failure (HF), type 2 diabetes (T2DM), and chronic kidney disease (CKD). Here, SLC5A2 is linked to chronic kidney disease.